SCHEMBL5824700

SCHEMBL5824700

COc1ccc(C(O)C(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GABBR2 O75899 1/20 0.44
GABBR1 Q9UBS5 1/20 0.44
ACP3 P15309 1/20 0.43
SLC2A1 P11166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11530900 0.94 LTA4H (0.50) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL12493635 0.85 ALDH1A1 (0.48) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL5865854 0.81 MEN1 (0.51) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL7127057 0.81 ALDH1A1 (0.64) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL2426161 0.81 GABBR2 (0.50) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL25375559 0.80 NPSR1 (0.47) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL25431280 0.80 NPSR1 (0.47) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL11507244 0.80 NPSR1 (0.51) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL6826547 0.79 AOC3 (0.49) AOC3ALDH1A1TSHRMAPK1TDP1
SCHEMBL11531665 0.79 FFAR1 (0.44) AOC3ALDH1A1TSHRMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160101188-A1 NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS UNIV CINCINNATI (US) 2016-04-14 US disclosed
WO-2014194250-A2 NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS UNIVERSITY OF CINCINNATI (US) 2014-12-04 WO disclosed
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US disclosed
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-21 US disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160101188-A1 NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS DCTD, TYMS, CDA AOC3 4228/4885ALDH1A1 2714/4885TSHR 4080/4885
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA AOC3 2810/4885ALDH1A1 2003/4885TSHR 293/4885
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA AOC3 3422/4885ALDH1A1 2059/4885TSHR 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.